'Tough decisions' as Sobi gears up for new hemophilia launch
This article was originally published in Scrip
Executive Summary
Geoffrey McDonough, president and CEO of Swedish Orphan Biovitrum (Sobi), says the rare disease-focused company has been making launch preparations for Elocta, its recombinant clotting factor VIII hemophilia therapy, for two years now. However, in a bid to maintain focus on its more promising commercial prospects, Sobi has made some tough decisions in the past few months, he noted, speaking at the Jefferies Global Healthcare Conference in London this week.